Research programme: cancer immunotherapeutics - Variagenics
Latest Information Update: 02 Jul 2004
At a glance
- Originator Variagenics
- Class Antibodies
- Mechanism of Action Immunostimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 02 Jul 2004 Discontinued - Preclinical for Cancer in USA (unspecified route)
- 16 Jul 2001 Preclinical trials in Cancer in USA (unspecified route)